The Illinois Department of Public Health (IDPH) is announcing two new COVID-19 oral antivirals, Paxlovid (Pfizer) and Molnupiravir (Merck), will be available in Illinois later this month.  The antivirals are for those with mild-to-moderate COVID-19 who are at high risk for becoming severely ill, including hospitalization or death.  Both antivirals will be available by prescription only and should be taken as soon as possible after being diagnosed and within five days of the beginning of symptoms. Paxlovid is expected to reduce the risk of hospitalizations by 89 percent and Molnupiravir by about 30 percent. Molnupiravir is meant for use when other treatment options are not available.

Molnupiravir is not authorized for use in patients who are pregnant or younger than 18 years of age because it may affect bone and cartilage growth.  Molnupiravir is intended to be used when other FDA-authorized treatments for COVID-19 are not accessible or are not clinically appropriate.  Providers must ensure that patients understand the safety risks of these therapeutics before prescribing them. In addition to the oral antivirals, people can still receive monoclonal antibody treatment (mAb) to help prevent COVID-19 from progressing to a point where a person needs to be hospitalized.  Unlike the new oral antivirals, mAb are administered intravenously (infusion) or through several shots.  Both require a prescription. More information on COVID-19 Treatment can be found at https://dph.illinois.gov/covid19/community-guidance/covid19-treatment.html.